Status:

COMPLETED

Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors

Lead Sponsor:

Massachusetts General Hospital

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to discover if intensive lifestyle changes (such as diet and increased physical activity) improve the body's sensitivity to insulin, and therefore help prevent diabetes an...

Detailed Description

* In this study, participants will be divided into two groups. One group will undergo intensive lifestyle changes (Lifestyle Intervention Group) designed by the Diabetes Prevention Group, and the othe...

Eligibility Criteria

Inclusion

  • Histologically confirmed prostate cancer
  • Current Hormone therapy with GnRH agonist of 3 months or longer
  • Overweight or obese (body mass index of 25kg/m2 or greater)
  • No other conditions that prevent intensive lifestyle intervention

Exclusion

  • History of diabetes mellitus requiring drug therapy
  • Hemoglobin Aic of 7% or greater
  • Symptomatic metastatic disease
  • Myocardial infarction within 6 months
  • Treatment with anabolic agents or metabolic agents known to affect insulin or glucose levels
  • Disease progression according to PSA Working Group Criteria

Key Trial Info

Start Date :

September 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2012

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00738140

Start Date

September 1 2007

End Date

September 1 2012

Last Update

July 11 2013

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02115

3

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115